Pancreatic Cancer Research

ResearcherTohoku UniversityNo recent work listed

Kei Kawaguchi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5110514735. Sources: OpenAlex.

Their work

Papers
22 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 6 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper

Papers 22

  1. Expression of Corticotropin-Releasing Hormone and Its Receptors May Be Associated With Survival Rate in Pancreatic Cancer. Co-author DOI 10.1016/j.gastha.2022.09.003↗
  2. What is the impact of zinc deficiency for pancreatectomies in patients with pancreatic ductal adenocarcinoma? Co-author DOI 10.1016/j.pan.2021.12.006↗
  3. Impact of Tumor-Derived DNA Testing in Peritoneal Lavage of Pancreatic Cancer Patients with and Without Occult Intra-Abdominal Metastases. Co-author DOI 10.1245/s10434-021-10997-w↗
  4. High Incidence of Lymph-node Metastasis in a Pancreatic-cancer Patient-derived Orthotopic Xenograft (PDOX) NOG-Mouse Model. Co-author DOI 10.21873/anticanres.15532↗
  5. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Co-author DOI 10.1007/s00595-020-02121-4↗
  6. Triple-Methyl Blockade With Recombinant Methioninase, Cycloleucine, and Azacitidine Arrests a Pancreatic Cancer Patient-Derived Orthotopic Xenograft Model. Co-author DOI 10.1097/mpa.0000000000001709↗
  7. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.08.022↗
  8. Stromal expression of hemopexin is associated with lymph-node metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0235904↗
  9. Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy. Co-author DOI 10.21873/anticanres.13726↗
  10. [Conversion Surgery for Locally Advanced Unresectable Pancreatic Cancer Treated with FOLFIRINOX Therapy and Proton Beam Therapy Combined with S-1 Chemotherapy-… Co-author PMID 32157015↗
  11. Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.06.016↗
  12. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Co-author DOI 10.1016/j.tice.2018.05.003↗
  13. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived… Co-author DOI 10.1080/15384101.2018.1445907↗
  14. Tumor targeting Salmonella typhimurium A1-R in combination with gemcitabine (GEM) regresses partially GEM-resistant pancreatic cancer patient-derived orthotopi… Co-author DOI 10.1080/15384101.2018.1480223↗
  15. Association between chronological depressive changes and physical symptoms in postoperative pancreatic cancer patients. Co-author DOI 10.1186/s13030-018-0132-1↗
  16. Intra-tumor L-methionine level highly correlates with tumor size in both pancreatic cancer and melanoma patient-derived orthotopic xenograft (PDOX) nude-mouse … Co-author DOI 10.18632/oncotarget.24264↗
  17. MK2461, a Multitargeted Kinase Inhibitor, Suppresses the Progression of Pancreatic Cancer by Disrupting the Interaction Between Pancreatic Cancer Cells and Ste… Co-author DOI 10.1097/mpa.0000000000000778↗
  18. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). Co-author DOI 10.18632/oncotarget.17667↗
  19. Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcita… First author DOI 10.1021/acs.molpharmaceut.5b00282↗
  20. [A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery]. Co-author PMID 25731467↗
  21. [A case of curatively resected locally advanced pancreatic cancer with combined resection of the portal vein and common hepatic artery after neoadjuvant chemot… Co-author PMID 24393951↗
  22. Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metab… First author DOI 10.1007/s11095-012-0728-2↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michiaki Unno · 22 shared papers, 2012–2023 · strength 1.88
  2. Fuyuhiko Motoi · 12 shared papers, 2012–2023 · strength 0.96
  3. Kei Nakagawa · 8 shared papers, 2014–2023 · strength 0.84
  4. Robert M. Hoffman · 9 shared papers, 2017–2022 · strength 0.77
  5. Michael Bouvet · 8 shared papers, 2017–2022 · strength 0.71
  6. Masamichi Mizuma · 7 shared papers, 2014–2022 · strength 0.68
  7. Tatsuyuki Takadate · 6 shared papers, 2019–2023 · strength 0.67
  8. Takanori Morikawa · 6 shared papers, 2014–2022 · strength 0.60
  9. Kentaro Miyake · 7 shared papers, 2018–2022 · strength 0.59
  10. Tatsuo Hata · 5 shared papers, 2019–2022 · strength 0.50
  11. Shuichi Aoki · 4 shared papers, 2020–2022 · strength 0.48
  12. Masahiro Iseki · 4 shared papers, 2019–2022 · strength 0.42
  13. Norihiko Sugisawa · 3 shared papers, 2019–2022 · strength 0.36
  14. Yu Katayose · 4 shared papers, 2014–2023 · strength 0.33
  15. Kyohei Ariake · 3 shared papers, 2018–2021 · strength 0.27
  16. Naoko Sato · 2 shared papers, 2018–2023 · strength 0.24
  17. Thinzar Min Lwin · 3 shared papers, 2017–2018 · strength 0.20
  18. Shimpei Maeda · 2 shared papers, 2020–2021 · strength 0.19
  19. Tetsuya Terasaki · 3 shared papers, 2012–2017 · strength 0.14
  20. Kazuharu Chiba · 1 shared paper, 2022 · strength 0.14
  21. Toru Furukawa · 1 shared paper, 2022 · strength 0.14
  22. Takashi Murakami · 2 shared papers, 2017–2018 · strength 0.13
  23. Ho Kyoung Hwang · 2 shared papers, 2017–2018 · strength 0.13
  24. Shinichi Egawa · 3 shared papers, 2012–2017 · strength 0.12
  25. Hiroto Nishino · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.